rdf:type |
|
lifeskim:mentions |
umls-concept:C0006118,
umls-concept:C0007257,
umls-concept:C0017636,
umls-concept:C0034656,
umls-concept:C0034897,
umls-concept:C0076080,
umls-concept:C0282460,
umls-concept:C1135135,
umls-concept:C1257890,
umls-concept:C1516985,
umls-concept:C2603343
|
pubmed:issue |
8
|
pubmed:dateCreated |
2009-3-9
|
pubmed:abstractText |
Approximately 50% of glioblastomas (GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In approximately 25% of instances, constitutively activated EGFR mutants are present. These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM.
|
pubmed:grant |
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-10728703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-1100130,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-11302336,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-12782577,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-14638850,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-15118073,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-15118125,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-15477552,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-15758009,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-15851741,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-15956649,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-16278407,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-16282176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-16443950,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-16818690,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-16914310,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-17239291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-17318210,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-17872411,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-18176118,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-2358840,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19204207-9504686
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Carmustine,
http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN Phosphohydrolase,
http://linkedlifedata.com/resource/pubmed/chemical/PTEN protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/epidermal growth factor receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/erlotinib,
http://linkedlifedata.com/resource/pubmed/chemical/temozolomide
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1527-7755
|
pubmed:author |
pubmed-author:ArmandJean-PaulJP,
pubmed-author:BaurainJean-FrancoisJF,
pubmed-author:BrandesAlba AAA,
pubmed-author:CamponeMarioM,
pubmed-author:CarpentierAntoine FAF,
pubmed-author:ClementPaul MPM,
pubmed-author:FrenayMarcM,
pubmed-author:GorliaThierryT,
pubmed-author:KletzlHeidemarieH,
pubmed-author:KlughammerBarbaraB,
pubmed-author:KouwenhovenMathilde C MMC,
pubmed-author:KrosJohan MJM,
pubmed-author:LacombeDenisD,
pubmed-author:RamplingRoyR,
pubmed-author:TaphoornMartin J BMJ,
pubmed-author:TosoniAliciaA,
pubmed-author:van den BentMartin JMJ
|
pubmed:issnType |
Electronic
|
pubmed:day |
10
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1268-74
|
pubmed:dateRevised |
2010-9-23
|
pubmed:meshHeading |
pubmed-meshheading:19204207-Adolescent,
pubmed-meshheading:19204207-Adult,
pubmed-meshheading:19204207-Aged,
pubmed-meshheading:19204207-Antineoplastic Agents,
pubmed-meshheading:19204207-Brain Neoplasms,
pubmed-meshheading:19204207-Carmustine,
pubmed-meshheading:19204207-Dacarbazine,
pubmed-meshheading:19204207-Female,
pubmed-meshheading:19204207-Glioblastoma,
pubmed-meshheading:19204207-Humans,
pubmed-meshheading:19204207-Male,
pubmed-meshheading:19204207-Middle Aged,
pubmed-meshheading:19204207-Neoplasm Recurrence, Local,
pubmed-meshheading:19204207-PTEN Phosphohydrolase,
pubmed-meshheading:19204207-Quinazolines,
pubmed-meshheading:19204207-Receptor, Epidermal Growth Factor
|
pubmed:year |
2009
|
pubmed:articleTitle |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
|
pubmed:affiliation |
Neuro-Oncology Unit, Daniel den Hoed Cancer Center, PO Box 5201, 3008AE Rotterdam, the Netherlands. m.vandenbent@erasmusmc.nl
|
pubmed:publicationType |
Journal Article
|